Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 70

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 70
---
 made for the benefit of the other parties to the Merger Agreement and may be intended not as statements of fact but rather as a way of allocating the risk to one of the parties if such statements made in the representations and warranties prove to be incorrect. Accordingly, you should not rely on the representations and warranties as current characterizations of factual information about TELO, TELI or Merger Sub, because they were made as of specific dates, may be intended merely as a risk allocation mechanism between TELI and Merger Sub on the one hand, and TELI on the other hand.

Management Following the Merger

Following the Merger, the combined company is expected to retain four of the current directors of TELO as were in office prior to the Merger, comprised of Matthew Pratt Whalen, CPA; Erez Aminov; Edward MacPherson, and Dr. Matthew Paul Del Giudice, with each until their respective successors are duly elected or appointed and qualified or their earlier death, resignation or removal

Regulatory Approvals

We are not aware of any federal, state, local or foreign regulatory requirements that must be complied with or approvals that must be obtained prior to completion of the merger pursuant to the merger agreement, other than compliance with applicable federal and state securities laws, the filing of articles of merger as required under the Florida Business Corporation Act and various state governmental authorizations.

Appraisal Rights and Dissenters’ Rights

Pursuant to Section 607.1302 of the Florida Business Corporation Act, the shareholders of TELO will not be entitled to appraisal rights or dissenters rights as a result of the merger.

Additional Information

For a detailed description of the Merger Agreement, including representations, warranties, covenants, and other terms, please refer to the full text of the Merger Agreement filed as Annex A to this Proxy Statement.

Pro Forma Financial Statements of TELO Following the Merger

The summary financial statements of TELO for
the nine months ended September 30, 2025 and pro forma financial statements for TELO following the Merger have been derived from our
unaudited financial statements not included in this prospectus but included in our Form 10-Q filed for the third quarter of 2025. The
pro-forma financial statements include a preliminary estimate of 34,380,950 shares to be issued to TELI in the Merger, and a price per
TELO share of $1.31, representing the closing price of TELO on